latest news releases from the newsroom
Digital Descriptor Systems Inc.
Digital Descriptor Systems, Inc. Announces 2nd Quarter '06 Results
SEA GIRT, N.J., Aug. 21, 2006 (PRIMEZONE) -- Digital Descriptor Systems, Inc. (Pink Sheets:DDSI) -- an industry leader in the development of Homeland Security and other commercial security related products -- today announced results for the period ending June 30, 2006. Revenues grew 40.9 percent, to $1,233,729, from second quarter 2005 revenues of $875,513. Gross profit rose over 210 percent, to $899,191 from $428,053 for the same period in 2005.
Directors Guild of America
DGA Announces Schedule for 59th Annual Awards
LOS ANGELES, Aug. 21, 2006 (PRIMEZONE) -- The Directors Guild of America has set its schedule for the 59th Annual DGA Awards, DGA President Michael Apted and Awards Committee Chairperson Howard Storm announced today. The 59th Annual DGA Awards Dinner will take place on Saturday, February 3, 2007.
Evergreen International Aviation, Inc.
Evergreen International Aviation, Inc. Announces Extension of Its Tender Offer for Its 12 Percent Senior Second Secured Notes Due 2010
MCMINNVILLE, Ore., Aug. 21, 2006 (PRIMEZONE) -- Evergreen International Aviation, Inc., an Oregon corporation ("Evergreen"), announced today that its pending offer to purchase any and all of its outstanding 12% Senior Second Secured Notes Due 2010 (CUSIP No. 30024DAF7) (the "Notes") previously scheduled to expire at 5:00 p.m., New York City time, on August 21, 2006, has been extended until 5:00 p.m., New York City time, on September 5, 2006, unless otherwise extended or earlier terminated. Except for the above change, all terms and conditions of the tender offer are unchanged and remain in full force and effect.
UCB Announces Agreement With Verus Pharmaceuticals for Commercialization of Twinject in Europe
BRUSSELS, Belgium, Aug. 21, 2006 (PRIMEZONE) -- Today UCB announced it has entered into an agreement with Verus Pharmaceuticals, Inc. (Verus), a pediatric-oriented specialty pharmaceutical company, for the commercialization of Twinject(r) in Europe. Twinject(r), a novel epinephrine auto-injector indicated for the emergency treatment of severe allergic reactions (anaphylaxis), was launched in the U.S. and Canada in 2005; it is the first and only product approved by the FDA and Health Canada that contains two doses of epinephrine in a single, compact device for self-administration.